Search / Trial NCT06228001

Holter of Movement in Patients With Amyotrophic Lateral Sclerosis.

Launched by LAURENT SERVAIS · Jan 18, 2024

Trial Information

Current as of October 08, 2024

Recruiting

Keywords

Actimyo Accelerometry Daily Living

Description

On each visit, participants will undergo a clinical examination with MRC sum score and Ashworth scores. Participants will perform few tests (6-minutes walk test (6MWT), dynamometric measure, electromyography, and will answer to some questionaires (dysphagia handicap scale, Revised Amyotrophic Lateral Sclerosis Functional Rating Scale). Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the moveme...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Clinically defined or probable diagnosis of ALS according to El Escorial criteria revised with Awaji's electro-diagnostic algorithm.
  • * Over 18 years old.
  • * Signed informed consent
  • * If patient on Riluzole, the dosage should be stable for 1 month and continued throughout the study period.
  • Exclusion Criteria:
  • * Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection.
  • * Any other previous or present pathology having an impact on motor function.
  • * Recent surgery or trauma (less than 6 months) in the upper or lower limbs.
  • * Prior neurological, endocrine, infectious, allergic, or chronic or acute inflammatory pathology in the three weeks preceding inclusion.
  • * Patients participating in an interventional clinical trial.

About Laurent Servais

Laurent Servais is a prominent clinical trial sponsor dedicated to advancing medical research through innovative and rigorous study designs. With a focus on neuromuscular disorders, the organization collaborates with leading researchers and institutions to develop effective therapies that improve patient outcomes. Committed to ethical standards and regulatory compliance, Laurent Servais prioritizes transparency and patient safety in all clinical endeavors, fostering an environment of collaboration and scientific excellence. Through its strategic initiatives, the sponsor aims to contribute significantly to the understanding and treatment of rare diseases, ultimately enhancing the quality of life for affected individuals.

Locations

Liège, , Belgium

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0